Quetiapine immediate release v. placebo for schizophrenia: Systematic review, meta-analysis and reappraisal

British Journal of Psychiatry

Volumn 206, Issue 5, 2015, Pages

  Hutton, Paul ^a   Taylor, Peter J ^b   Mulligan, Lee ^c   Tully, Sarah ^d   Moncrieff, Joanna ^e  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; QUETIAPINE; NEUROLEPTIC AGENT;

ANESTHESIA COMPLICATION; ARTICLE; BODY WEIGHT DISORDER; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; HOSPITAL CARE; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SCHIZOPHRENIA; SEDATION; SELF REPORT; SOCIAL INTERACTION; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT GAIN; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; HUMANS; QUALITY OF LIFE; QUETIAPINE FUMARATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SELF REPORT; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84929353117     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.114.154377     Document Type: Article

References (52)

1. National Prescribing Centre. Schizophrenia Data Focussed Commentary. NPC, 2010 (http://www.npc.nhs.uk/therapeutics/cns/schizophrenia/resources/dfc-schizophrenia.pdf).
2. Medicines and Healthcare Products Regulatory Authority. UKPAR Seroquel XL 50mg, 200mg, 300mg & 400mg prolonged-release tablets. MHRA, 2008.
3. Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Database Syst Rev 2004; 2: CD000967.
4. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are secondgeneration antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 2009; 14: 429-47.
5. Hamer RM, Simpson PM. Last observation carried forward versus mixed models in the analysis of psychiatric clinical trials. Am J Psychiatry 2009; 166: 639-41.
6. Hutton P, Morrison AP, Yung AR, Taylor PJ, French P, Dunn G. Effects of drop-out on efficacy estimates in five Cochrane reviews of popular antipsychotics for schizophrenia. Acta Psychiatr Scand 2012; 126: 1-11.
7. Xia J, Adams C, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Losing participants before the end of the trial erodes credibility of findings. Psychiatr Bull 2009; 33: 254-7.
8. Leucht S, Heres S, Hamann J, Kane JM. Methodological issues in current antipsychotic drug trials. Schizophr Bull 2008; 34: 275-85.
9. Rabinowitz J, Davidov O. The association of dropout and outcome in trials of antipsychotic medication and its implications for dealing with missing data. Schizophr Bull 2008; 34: 286-91.
10. Leucht S, Kane JM, Etschel E, Kissling W, Hamann J, Engel RR. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 2006; 31: 2318-25.
11. Thwin SS, Hermes E, Lew R, Barnett P, Liang M, Valley D, et al. Assessment of the minimum clinically important difference in quality of life in schizophrenia measured by the Quality of Well-Being Scale and disease-specific measures. Psychiatry Res 2013; 209: 291-6.
12. Hermes ED, Sokoloff D, Stroup TS, Rosenheck RA. Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). J Clin Psychiatry 2012; 73: 526-32.
13. Ebrahim S, Akl EA, Mustafa RA, Sun X, Walter SD, Heels-Ansdell D, et al. Addressing continuous data for participants excluded from trial analysis: a guide for systematic reviewers. J Clin Epidemiol 2013; 66: 1014-21, e1.
14. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean? Schizophr Res 2005; 79: 231-8.
15. Furukawa TA, Cipriani A, Barbui C, Brambilla P, Watanabe N. Imputing response rates from means and standard deviations in meta-analyses. Int Clin Psychopharmacol 2005; 20: 49-52.
16. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Collaboration, 2011.
17. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a metaanalysis. Lancet 2009; 373: 31-41.
18. Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. Am J Psychiatry 2010; 167: 686-93.
19. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382: 951-62.
20. Leucht S, Rothe P, Davis JM, Engel RR. Equipercentile linking of the BPRS and the PANSS. Eur Neuropsychopharmacol 2013; 23: 956-9.
21. National Institute for Health and Clinical Excellence. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary Care and Secondary Care (Update). NICE, 2009.
22. Bagnall AM, Jones L, Ginnelly L, Lewis R, Glanville J, Gilbody S, et al. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess 2003; 7: 1-193.
23. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407-15.
24. Schennach-Wolff R, Obermeier M, Seemuller F, Jager M, Schmauss M, Laux G, et al. Does clinical judgment of baseline severity and changes in psychopathology depend on the patient population? Results of a CGI and PANSS linking analysis in a naturalistic study. J Clin Psychopharmacol 2010; 30: 726-31.
25. Man-Son-Hing M, Laupacis A, O'Rourke K, Molnar FJ, Mahon J, Chan KB, et al. Determination of the clinical importance of study results. J Gen Intern Med 2002; 17: 469-76.
26. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-6.
27. Leucht S, Davis JM, Engel RR, Kissling W, Kane JM. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand Suppl 2009; 438: 7-14.
28. Samara MT, Spineli LM, Furukawa TA, Engel RR, Davis JM, Salanti G, et al. Imputation of response rates from means and standard deviations in schizophrenia. Schizophr Res 2013; 151: 209-14.
29. Harbord RM, Higgins JPT. Meta-regression in STATA. Stata J 2008; 8: 493-519.
30. Lundbeck. Synopsis - Study 11915A: a one-year multi-national, multi-centre, randomised, double-blind, parallel-group, fixed-dose bifeprunox study combining a 12-week placebo-controlled, quetiapine-referenced phase with a 12-month quetiapine-controlled phase in patients with schizophrenia. Lundbeck, 2010.
31. Lundbeck. Synopsis - Study 11916A: a one-year multi-national, multi-centre, randomised, double-blind, parallel-group, fixed-dose bifeprunox study combining a 12-week placebo-controlled, quetiapine-referenced phase with a 12-month quetiapine-controlled phase in patients with schizophrenia. Lundbeck, 2010.
32. Arvanitis L, Scott M. A multicenter, double blind, randomized, controlled, multiple fixed dose and dose regimen comparison of SEROQUELTM (ICI 204,636) and haloperidol in the prevention of psychotic relapse in outpatients with chronic or subchronic schizophrenia (5077IL/0015). AstraZeneca,1996.
33. Perlis RH, Ostacher M, Fava M, Nierenberg AA, Sachs GS, Rosenbaum JF. Assuring that double-blind is blind. Am J Psychiatry 2010; 167: 250-2.
34. Treadwell JR, Uhl S, Tipton K, Shamliyan T, Viswanathan M, Berkman ND, et al. Assessing equivalence and noninferiority. J Clin Epidemiol 2012; 65: 1144-9.
35. Spielmans GI, Parry PI. From evidence-based medicine to marketing-based medicine: evidence from internal industry documents. J Bioeth Inq 2010; 7: 13-29.
36. Potkin SG, Gharabawi GM, Greenspan AJ, Mahmoud R, Kosik-Gonzalez C, Rupnow MF, et al. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res 2006; 85: 254-65.
37. Canuso CM, Dirks B, Carothers J, Kosik-Gonzalez C, Bossie CA, Zhu Y, et al. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry 2009; 166: 691-701.
38. Arvanitis LA, Miller BG. Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997; 42: 233-46.
39. Lindenmayer JP, Brown D, Liu S, Brecher M, Meulien D. The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study. Psychopharmacol Bull 2008; 41: 11-35.
40. Findling RL, McKenna K, Earley WR, Stankowski J, Pathak S. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol 2012; 22: 327-42.
41. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997; 54: 549-57.
42. Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. J Clin Psychopharmacol 1996; 16: 158-69.
43. Kahn RS, Schulz SC, Palazov VD, Reyes EB, Brecher M, Svensson O, et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68: 832-42.
44. Cutler AJ, Tran-Johnson T, Kalali A, Astrom M, Brecher M, Meulien D. A failed 6-week, randomized, double-blind, placebo-controlled study of once-daily extended release quetiapine fumarate in patients with acute schizophrenia: lessons learned. Psychopharmacol Bull 2010; 43: 37-69.
45. Chen EY, Hui CL, Lam MM, Chiu CP, Law CW, Chung DW, et al. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ 2010; 341: c4024.
46. Agid O, Siu CO, Potkin SG, Kapur S, Watsky E, Vanderburg D, et al. Metaregression analysis of placebo response in antipsychotic trials, 1970-2010. Am J Psychiatry 2013; 170: 1335-44.
47. Leucht S, Heres S, Davis JM. Increasing placebo response in antipsychotic drug trials: let's stop the vicious circle. Am J Psychiatry 2013; 170: 1232-4.
48. Mallinckrodt CH, Zhang L, Prucka WR, Millen BA. Signal detection and placebo response in schizophrenia: parallels with depression. Psychopharmacol Bull 2010; 43: 53-72.
49. Hamann J, Kissling W, Leucht S. How long do psychiatrists wait for response before they switch to another antipsychotic? Psychopharmacol Bull 2007; 40: 149-54.
50. Wieseler B, Kerekes MF, Vervoelgyi V, McGauran N, Kaiser T. Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications. BMJ 2012; 344: d8141.
51. Hough DW, Natarajan J, Vandebosch A, Rossenu S, Kramer M, Eerdekens M. Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol 2011; 26: 25-34.
52. Chapel S, Hutmacher MM, Haig G, Bockbrader H, de Greef R, Preskorn SH, et al. Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation. J Clin Pharmacol 2009; 49: 1297-308.